Jordan-based Hikma Pharmaceuticals is planning to buy 30% stake in Mumbai-based API maufacturing firm Unimark Remedies Limited.
According to the news, the deal value is expected to be around Rs 150 crore, valuing the company at around Rs.500 Cr.
Founded in 1978 by Samih Darwazah, Hikma is a branded generic company that operates primarily in North America and the Middle East (MENA region). Its core products are anti-infectives, and the company has stated its intent to focus growth on cardiovascular, central nervous system, and diabetes.
No comments:
Post a Comment